(S)-N-(piperidin-3-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-N-(piperidin-3-yl)acetamide
• 英文别名: (S)-N-Piperidin-3-yl-acetamide；N-[(3S)-piperidin-3-yl]acetamide
• 化学式: C₇H₁₄N₂O
• mdl: MFCD05022483
• 分子量: 142.201
• InChiKey: BCXSCZDWARFWAW-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-N-(piperidin-3-yl)acetamide 、 乙醛 在 sodium hydroxide 、 水 、 Sodium sulfate-III 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以to yield (S)—N-(1-ethylpiperidin-3-yl)acetamide (22) (689 mg, 80%)的产率得到(S)-N-(1-ethylpiperidin-3-yl)acetamide
  参考文献：
  名称：

  INHIBITION OF OLIG2 ACTIVITY

  摘要：

  本文描述了一些抑制Olig2活性的化合物和药物组合物，同时还描述了使用这些Olig2抑制剂的方法，单独或与其他化合物组合，用于治疗癌症和其他疾病。特别是，这些Olig2抑制剂可以用于治疗胶质母细胞瘤。

  公开号：

  US20160237069A1
• 作为产物：
  描述：

  (S)-1-苄氧羰基-3-氨基哌啶 在 4-二甲氨基吡啶 、 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 20.0h， 生成 (S)-N-(piperidin-3-yl)acetamide
  参考文献：
  名称：

  [EN] RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE RAS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI

  摘要：

  There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, for example abnormal RAS activity caused by a mutation in RAS, including cancers with a mutated RAS. (I)

  公开号：

  WO2023060362A1

文献信息

• [EN] PYRAZOLYLAMINOPURINES AS ITK INHIBITORS<br/>[FR] PYRAZOLYLAMINOPURINES EN TANT QU'INHIBITEURS DE LA TYROSYNE KINASE (ITK)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016091916A1

  公开（公告）日：2016-06-16

  Provided are pyrazolylaminopurine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula I or II, stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where n, R1, R2, R3, R4, R5, R6 and R7 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by ITK kinase in a patient.

  提供了一种抑制ITK激酶的吡唑基氨基嘌呤化合物，包含这些化合物的组合物以及治疗由ITK激酶介导的疾病的方法。具体来说，提供了符合式I或II的化合物，立体异构体，互变异构体，溶剂合物，前药或其药用可接受的盐，其中n，R1，R2，R3，R4，R5，R6和R7在此处定义，包含该化合物和药用可接受的载体的药物组合物，使用该化合物或组合物进行治疗的方法，例如，用于治疗患有由ITK激酶介导的疾病或病况的患者。
• OXINDOLE DERIVATIVES
  申请人：Chen Li

  公开号：US20080081810A1

  公开（公告）日：2008-04-03

  There is provided compounds of the formula wherein R 6 , V, W, X, Y, Q and n are as described. The compounds exhibit activity as anticancer agents.

  提供的化合物具有以下结构式，其中R6、V、W、X、Y、Q和n如所述。这些化合物表现出抗癌药物的活性。
• Indeno [1,2-c]pyrazol-4-ones and their uses
  申请人：——

  公开号：US20010027195A1

  公开（公告）日：2001-10-04

  The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): 1 that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

  本发明涉及合成一种新类别的indeno[1,2-c]pyrazol-4-ones化合物，其化学式为(I):1，这些化合物是一类名为细胞周期依赖性激酶的酶的强效抑制剂，与催化亚基cdk1-9及其调节亚基cyclins A-H有关。本发明还提供了一种新颖的治疗癌症或其他增生性疾病的方法，即通过给予这些化合物中的一种或其药用可接受的盐形式的治疗有效剂量。另外，可以通过给予本发明化合物之一与一种或多种其他已知的抗癌或抗增生剂的治疗有效组合来治疗癌症或其他增生性疾病。
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：SAREUM LTD

  公开号：WO2015032423A1

  公开（公告）日：2015-03-12

  The invention provides a compound which is an amide of the formula (2): or a salt or stereoisomer thereof; wherein: R7 is selected from chlorine and fluorine; R3, R4, R5 and R6 are each independently selected from hydrogen, fluorine and chlorine; n is 0, 1 or 2; Q1 is selected from C(=O), S(=O) and SO2; A is absent or is NR2; R1 is selected from: - hydrogen; - an optionally substituted C1-6 non-aromatic hydrocarbon group; and - 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings being optionally substituted; R2 is selected from hydrogen and C1-4 alkyl; or NR1R2 forms an optionally substituted 4- to 7-membered non-aromatic nitrogen- containing heterocyclic ring optionally containing a second heteroatom ring member selected from nitrogen and oxygen; with the provisos that: (i) no more than two of R3 to R6 are other than hydrogen; and (ii) when R7 and R6 are both fluorine, then one of R3 to R5 is chlorine or fluorine and/or R1-A-Q1 is selected from ethylsulfonyl and isopropylsulfonyl. Also provided are pharmaceutical compositions containing the compounds and their therapeutic uses.

  本发明提供的化合物是公式（2）的酰胺或其盐或立体异构体；其中：R7从氯和氟中选择；R3、R4、R5和R6各自独立地从氢、氟和氯中选择；n为0、1或2；Q1从C（=O）、S（=O）和SO2中选择；A不存在或为NR2；R1从：-氢；-可选择取代的C1-6非芳香烃基；和-含有一个或两个杂原子环成员（选自O、N和S）的3-至7元非芳香碳环和杂环，并且是由七个至九个环成员的桥接双环杂环，其中一个或两个是氮原子，所述碳环和杂环以及桥接双环杂环可选择取代；R2从氢和C1-4烷基中选择；或NR1R2形成一个可选择取代的4-至7元非芳香含氮杂环，可选择包含第二个杂原子环成员，选自氮和氧；但前提是：（i）R3至R6中不超过两个不是氢；（ii）当R7和R6均为氟时，那么R3至R5中的一个为氯或氟和/或R1-A-Q1选择自乙基磺酰基和异丙基磺酰基。还提供了含有该化合物的药物组合物及其治疗用途。
• PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS
  申请人：Gut Ruggeri Sally

  公开号：US20120259115A1

  公开（公告）日：2012-10-11

  This invention relates to methods and intermediates useful for the synthesis of pyrrolo [2,3-d] pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.

  本发明涉及用于合成吡咯并[2,3-d]嘧啶化合物的方法和中间体。具体地，本发明揭示了用于合成3-(3R,4R)-4-甲基-(7H-吡咯并[2,3-d]嘧啶-4-基)-氨基}-哌啶-1-基)-3-氧代-丙腈及其相应的柠檬酸盐的新合成方法和中间体。